Evolus, Inc. ( (EOLS) ) has released its Q1 earnings. Here is a breakdown of the information Evolus, Inc. presented to its investors.
Evolus, Inc., a global performance beauty company, specializes in aesthetic injectables, focusing on consumer-centric brands and innovative digital platforms. The company recently reported its first-quarter 2025 financial results, highlighting a global net revenue of $68.5 million, marking a 15.5% increase from the previous year, despite a slower market environment. Evolus also launched Evolysse, which has shown strong initial performance, contributing to the company’s reaffirmed revenue guidance for the year.
Key financial metrics reveal a GAAP operating loss of $15.2 million and a non-GAAP operating loss of $5.5 million, with expectations to achieve positive non-GAAP operating income by the end of 2025. The company’s gross profit margin stood at 68.1%, with adjusted margins slightly higher at 69.2%. Evolus continues to expand its market presence, with Jeuveau’s market share gains and the successful launch of Evolysse, driving growth.
The company’s strategic focus includes expanding its product portfolio with the upcoming launches of Evolysse Sculpt and Evolysse Lips in the coming years. Evolus aims to achieve significant revenue growth, targeting $700 million by 2028, leveraging its existing infrastructure and new product introductions. The company remains committed to enhancing its market position through continued investment in its product lines and expanding its global reach.
Looking ahead, Evolus maintains a positive outlook, expecting total net revenues for 2025 to range between $345 million and $355 million, with a focus on achieving sustained growth and profitability. The management’s confidence is bolstered by the strong market adoption of its products and strategic initiatives aimed at capturing a larger share of the aesthetic injectables market.